Christopher Bull Granger, MD

Professor of Medicine
Professor in the School of Nursing
Member in the Duke Clinical Research Institute
Campus mail 200 Morris Street, Durham, NC 27701
Phone (919) 668-8900
Email address grang001@mc.duke.edu

Research:
My primary research interest is in conduct and methodology of large randomized clinical trials in heart disease. I have led a number of large international clinical studies in heart attacks, unstable angina, heart failure, and atrial fibrillation. I have lead clinical studies of blood thinners and coronary intervention for heart attacks, stroke prevention in atrial fibrillation, and prevention of heart attack for patients with coronary artery disease. I have been co-director of the Reperfusion of Acute MI in Carolina Emergency Departments (RACE) project that is a North Carolina state-wide program to improve reperfusion care for acute myocardial infarction. I serve as the Chairman of the American Heart Association Mission: Lifeline program to improve heart attack care nationally as well as the American College of Cardiology/American Heart Association guideline committee for heart attack care. I have also studied the effects of genetic variation on heart disease. I work with the National Institute of Health and the Federal Drug Administration on evaluation of heart disease and of new drugs. I have developed tools to predict which patients are at risk for death, heart attack, and need for hospitalization.

Education and Training

  • Fellow in Cardiology, Medicine, Duke University, 1988 - 1990
  • Chief Medical Resident, Medicine, University of Colorado Denver, School of Medicine, 1987 - 1988
  • Medical Resident, Medicine, University of Colorado Denver, School of Medicine, 1984 - 1987
  • M.D., University of Connecticut, 1984

Publications

Carnicelli, Anthony P., Sana M. Al-Khatib, Denis Xavier, Frederik Dalgaard, Peter D. Merrill, Daniel M. Wojdyla, Basil S. Lewis, et al. “Premature permanent discontinuation of apixaban or warfarin in patients with atrial fibrillation.” Heart, September 16, 2020. https://doi.org/10.1136/heartjnl-2020-317229.

PMID
32938772
Full Text

Hijazi, Ziad, Christopher B. Granger, Stefan H. Hohnloser, Johan Westerbergh, Johan Lindbäck, John H. Alexander, Matyas Keltai, et al. “Association of Different Estimates of Renal Function With Cardiovascular Mortality and Bleeding in Atrial Fibrillation.” J Am Heart Assoc 9, no. 18 (September 15, 2020): e017155. https://doi.org/10.1161/JAHA.120.017155.

PMID
32865097
Full Text

Hijazi, Ziad, Jonas Oldgren, Johan Lindbäck, John H. Alexander, Marco Alings, Raffaele De Caterina, John W. Eikelboom, et al. “Evaluation of the Age, Biomarkers, and Clinical History-Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials.” Jama Netw Open 3, no. 9 (September 1, 2020): e2015943. https://doi.org/10.1001/jamanetworkopen.2020.15943.

PMID
32936298
Full Text

Samsky, Marc D., Adam D. DeVore, Colleen K. McIlvennan, Christopher B. Granger, Bradi B. Granger, Adrian F. Hernandez, G Michael Felker, et al. “Heart Failure Clinical Trial Operations During the COVID-19 Pandemic: Results From a Multicenter Survey.” Circ Heart Fail 13, no. 9 (September 2020): e007456. https://doi.org/10.1161/CIRCHEARTFAILURE.120.007456.

PMID
32700547
Full Text

Thulin, Åsa, Johan Lindbäck, Christopher B. Granger, Lars Wallentin, Lars Lind, and Agneta Siegbahn. “Extracellular vesicles in atrial fibrillation and stroke.” Thromb Res 193 (September 2020): 180–89. https://doi.org/10.1016/j.thromres.2020.07.029.

PMID
32717643
Full Text

Fanaroff, Alexander C., Robert M. Califf, Robert A. Harrington, Christopher B. Granger, John J. V. McMurray, Manesh R. Patel, Deepak L. Bhatt, et al. “Randomized Trials Versus Common Sense and Clinical Observation: JACC Review Topic of the Week.” J Am Coll Cardiol 76, no. 5 (August 4, 2020): 580–89. https://doi.org/10.1016/j.jacc.2020.05.069.

PMID
32731936
Full Text

Lopes, Renato D., Ariane Vieira Scarlatelli Macedo, Pedro Gabriel Melo de Barros E Silva, Renata Junqueira Moll-Bernardes, Andre Feldman, Guilherme D’Andréa Saba Arruda, Andrea Silvestre de Souza, et al. “Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial.” Am Heart J 226 (August 2020): 49–59. https://doi.org/10.1016/j.ahj.2020.05.002.

PMID
32502882
Full Text

Marquis-Gravel, Guillaume, Shamir R. Mehta, Marco Valgimigli, Glenn N. Levine, Franz-Josef Neumann, Christopher B. Granger, Francesco Costa, et al. “A Critical Comparison of Canadian and International Guidelines Recommendations for Antiplatelet Therapy in Coronary Artery Disease.” Can J Cardiol 36, no. 8 (August 2020): 1298–1307. https://doi.org/10.1016/j.cjca.2019.12.013.

PMID
32553812
Full Text

Garcia, Crystal J., Kevin Haynes, Sean D. Pokorney, Nancy D. Lin, Cheryl McMahill-Walraven, Vinit Nair, Lauren Parlett, et al. “Practical challenges in the conduct of pragmatic trials embedded in health plans: Lessons of IMPACT-AFib, an FDA-Catalyst trial.” Clin Trials 17, no. 4 (August 2020): 360–67. https://doi.org/10.1177/1740774520928426.

PMID
32589056
Full Text

Sullivan, Alexander E., Michael G. Nanna, Sunil V. Rao, Sarah Cantrell, C Michael Gibson, Freek W. A. Verheugt, Eric D. Peterson, et al. “A systematic review of randomized trials comparing double versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.” Catheter Cardiovasc Interv 96, no. 2 (August 2020): E102–9. https://doi.org/10.1002/ccd.28535.

PMID
31713326
Full Text

Pages